Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Summary of Q&ASecond quarter of the fiscal year ending September 20266 items taken from the company’s own explanation
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
Whether the upward revision is one-off or sustainable, reasons for the decline in the Medical Support Business profit margin, seasonality of blood-derived processing outsourcing services, the overseas business's sales and operating profit variance versus budget, synergies with SBC Medical Group, reasons for emphasizing research and development and intellectual property, and the kind of company the company aims to become over the medium to long termBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Medical Support Business: increase in the number of affiliated clinics, higher utilization rates, higher processing volumes per day, and synergies with SBC Medical Group. Overseas business: progress in sales of high-value-added products with higher gross margins
New initiatives
Consideration of expansion through new services and joint development with SBC Medical Group, as well as in regenerative medicine-related fields, and the development of a healthcare platform combining research, intellectual property, a network of medical institutions and product developmentKey KPIsA metric the company considers important as a management benchmark.
Number of affiliated clinics, utilization rate, and processing volume per day (figures not disclosed)Unit price and quantity metricsThese figures show sales broken down by price and volume.
Processing volume per day (figure not disclosed)Segment results
Overseas business: sales were +80 versus budget, and operating profit was +87 versus budget (the units are not specified in the text)| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Second quarter of the fiscal year ending September 2026 |
| Segment results | Overseas business: sales were +80 versus budget, and operating profit was +87 versus budget (the units are not specified in the text) |
| Breakdown of Factors Affecting the Change | Medical Support Business: increase in the number of affiliated clinics, higher utilization rates, higher processing volumes per day, and synergies with SBC Medical Group. Overseas business: progress in sales of high-value-added products with higher gross margins |
| Key KPIs | Number of affiliated clinics, utilization rate, and processing volume per day (figures not disclosed) |
| Unit price and quantity metrics | Processing volume per day (figure not disclosed) |
| Key points of the Q&A | Whether the upward revision is one-off or sustainable, reasons for the decline in the Medical Support Business profit margin, seasonality of blood-derived processing outsourcing services, the overseas business's sales and operating profit variance versus budget, synergies with SBC Medical Group, reasons for emphasizing research and development and intellectual property, and the kind of company the company aims to become over the medium to long term |
| New initiatives | Consideration of expansion through new services and joint development with SBC Medical Group, as well as in regenerative medicine-related fields, and the development of a healthcare platform combining research, intellectual property, a network of medical institutions and product development |
Items this document does not state (23)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical Support Business, the number of affiliated clinics, utilization rates and processing volumes per day are all increasing simultaneously. Some synergies with SBC Medical Group have also begun to emerge. In the overseas business, sales of high-value-added products with higher gross margins progressed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.